Exosomes are derived from cell vesicles present in almost of eukaryotic fluids which includes cultured media for cell culture, urine and blood. Exosomes are nanovescicles discharged into extracellular environment upon fusion of vesicle with plasma membrane. Its molecular content is as similar as person’s identity by fingerprint. As exosomes are accessible easily through body fluids such as urine and blood, they can be represented as a significant biomedical tool. Thus exosomes diagnostics can be used as a biomarkers especially for prognosis of malicious tumors in human body.
According to a recent research by Future Market Insights, the global exosomes diagnostics and therapeutics market is expected to register an excellent CAGR of 23.1% during the forecast period 2017 – 2027. The global exosomes diagnostics and therapeutics market was estimated to be valued at US$ 19.0 Mn in 2016 and expected to reach at US$ 152.0 Mn by the end of 2027. An analysts associated with the market researcher has answered some of the key queries regarding the expansion of the global exosomes diagnostics and therapeutics market, and has revealed valuable insights as follows:
What is the presumptive scenario for exosomes diagnostics and therapeutics market in North America?
North America region is highly likely to reflect robust growth opportunities for exosomes diagnostic and therapeutic market in the near future. The exosomes diagnostic and therapeutic market in this region is projected to touch a high market valuation by end of 2027 and is estimated to grow at a significant CAGR during the forecast period. United States is observed as a main contributor for revenue growth of the market owing to increasing government spending in healthcare industry in US coupled with the integration of advance technologies in upgradation of diagnostics tools and therapeutics in the region.
After North America, what is your uptake on growth opportunities for APEJ?
The exosomes diagnostic and therapeutic market in Asia Pacific excluding Japan (APEJ) region is anticipated to grow at a moderate pace in the coming years. Developing economies of APEJ such as China and India are expected to witness rise in adoption of exosomes diagnostics and therapeutics in the region. Growing healthcare facilities in these countries coupled with the favorable government policies and medical schemes is likely to have positive impact on market growth of exosomes diagnostic and therapeutic during the forecast period. The exosomes diagnostic and therapeutic market in APEJ was valued nearly US$ 3 Mn in 2017 and is expected to reach a value more than US$ 28 Mn by the end of forecast period. The market is poised to reflect a healthy CAGR of 25.4% during the forecast period 2017-2027.
As per FMI’s demarcation on exosomes diagnostics and therapeutics market, where do you think companies attain prolific opportunities in terms of application?
Based on the application, exosomes diagnostics is highly likely to remain prevalent followed by exosomes therapeutics. Rising application of exosomes diagnostics is expected to reflect a value of US$ 90 Mn whereas therapeutics is anticipated to register a significant CAGR of 29.0% by the end of forecast period
Which product in exosomes diagnostics and therapeutics market is likely to witness strong growth?
Depending upon the product types, reagents and kits are likely to gain high traction due to rising use in exosomes diagnostics and therapeutics. The reagents and kits are anticipated to register a CAGR of 28.2% during the forecast period. Followed by this, the software is expected to witness fast growth stimulating the growth of the global market.
Who are the leading manufacturers to contribute towards the growth of exosomes diagnostics and therapeutics market?
Market players involved in the manufacture of exosomes diagnostic and therapeutic are strongly focused on raising capital in order to launch innovative products and increase spending on research and development activities through venture sponsoring. Key companies such as Exiqon A/S (Aethlon Medical, Inc.), NanoSomix, Inc., Thermo Fisher Scientific, Inc., Capricor Therapeutics, Inc., Exosome Diagnostics, Inc., System Biosciences, Inc. and NX PHARMAGEN are mostly operating in North America thereby account for majority of value share in exosomes diagnostics and therapeutics market.
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-6379
